Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-02-27
|
Rekynda™ (bremelanotide) |
pre-menopausal women diagnosed with hypoactive sexual desire disorder (HSDD) |
3 |
Amag Pharmaceuticals (USA - MA) Palatin Technologies (USA - NJ) |
Women health |
2017-02-27
|
Trulance™ (plecanatide) |
chronic idiopathic constipation (CIC) |
3 |
Synergy Pharmaceuticals (USA - NY) |
Digestive diseases - Gastrointestinal diseases - Inflammatory diseases |
2017-02-24
|
Taksta™ (CEM-102, sodium fusidate, sodium salt of fusidic acid) |
acute bacterial skin and skin structure infections (ABSSSI) |
3 |
Cempra (USA - NC) |
Infectious diseases |
2017-02-24
|
TroVax® (MVA-5T4 Immunotherapy) |
colorectal cancer |
2 |
Oxford Biomedica (UK) |
Cancer - Oncology (UK) |
2017-02-24
|
V212 |
herpes zoster |
3 |
Merck&Co (USA - NJ) |
Infectious diseases |
2017-02-24
|
IMO-2125 in combination with ipilimumab or pembrolizumab |
patients with metastatic melanoma with disease that is refractory to PD-1 inhibitors. |
1-2 |
Idera Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2017-02-23
|
DX-2930 - lanadelumab |
prevention of hereditary angioedema (HAE) attacks |
1b |
Dyax (USA - MA), now Shire (UK - USA) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-02-23
|
Baremsis™ - APD421 (amisulpride - intravenous formulation of a currently marketed dopamine D2 antagonist for the new use of prevention and treatment of nausea & vomiting) |
post-operative nausea & vomiting (PONV) |
|
Acacia Pharma (UK) |
Gastrointestinal diseases - Digestive diseases |
2017-02-23
|
Toca 511 & Toca FC |
glioblastoma multiforme, anaplastic astrocytoma |
2-3 |
Tocagen (USA - CA) |
Cancer - Oncology |
2017-02-23
|
GLPG2451 and GLPG2222 |
cystic fibrosis |
1 |
Galapagos (Belgium) |
Rare diseases - Genetic diseases |
2017-02-23
|
tivozanib (N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N´-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate) |
renal cell carcinoma (RCC) |
3 |
Aveo Oncology (USA - MA) |
Cancer - Oncology |
2017-02-23
|
antiviral molecules with potential for Dengue virus treatment |
dengue fever |
preclinical |
Abivax (France) |
Infectious diseases |
2017-02-23
|
Bronchitol® (mannitol) |
cystic fibrosis |
3 |
Pharmaxis (Australia) |
Rare diseases - Genetic diseases |
2017-02-21
|
MOR107 (formerly LP2) |
|
1 |
Lanthio Pharma, Morphosys ' subsidiary (The Netherlands) |
|
2017-02-21
|
ATX-MS-1467 |
relapsing multiple sclerosis (RMS) |
2a |
Apitope (UK) |
Autoimmune diseases |
2017-02-20
|
savolitinib |
pulmonary sarcomatoid carcinoma |
2 |
Hutchison China MediTech Limited "ChiMed" (China) |
Cancer - Oncology |
2017-02-19
|
Tecentriq® (atezolizumab) and Avastin® (bevacizumab) |
renal cell carcinoma |
2 |
Roche (Switzerland) |
Cancer - Oncology |
2017-02-17
|
Entyvio® (vedolizumab) |
moderately to severely active ulcerative colitis, Crohn's disease |
3 |
Takeda Pharmaceutical (Japan) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2017-02-17
|
tivantinib (ARQ 197) |
hepatocellular carcinoma |
3 |
ArQule (USA - MA) Daiichi Sankyo (Japon) |
Cancer - Oncology |
2017-02-17
|
CT-P13 - Inflectra®/Remsima® (biosimilar infliximab) |
Crohn's disease |
3 |
Celltrion Healthcare (South Korea) Pfizer (USA - NY) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |